VIVE - Viveve Medical EPS beats by $0.67 beats on revenue

Viveve Medical (VIVE): FY GAAP EPS of -$16.56 beats by $0.67.Revenue of $5.48M (-16.6% Y/Y) beats by $0.1M.Cash and cash equivalents were $6.5 million as of December 31, 2020, compared to $13.3 million as of December 31, 2019."Pending positive PURSUIT trial results in mid-2022 and subsequent FDA approval, our non-invasive SUI treatment has the potential to treat an estimated 25-30 million women in the U.S. who suffer from SUI." said Scott Durbin, CEO.Shares +1.54%.Press Release

For further details see:

Viveve Medical EPS beats by $0.67, beats on revenue